17,261 trials
Meningococcal Meningitis · Tetanus · Diphtheria
Primary: Number of Participants With Antibodies Against Diphtheria and Tetanus at ≥ 1.0 IU/mL After DAPTACEL Vaccination — 249; 238; 246; 236 Participants
Influenza
Primary: Number of Participants With Local and Systemic Symptoms Post Vaccination 1 (Day 0) — 0; 13; 2; 3 participants
Chronic Obstructive Pulmonary Disease
Primary: Incidence of Adverse Events — 13; 17 Participants
Keloid
Primary: The Primary Purpose of This Study Will be to Gain Preliminary Safety Experience With Apligraf in the Keloid Indication. The Number of Participants Experiencing AEs is…
Arterial Occlusive Disease · Peripheral Vascular Disease · Ischemia
Primary: Wound Healing (Change in Total Wound Area of All Ischemic Ulcers) — 5.75; 12.600; 15.766; 12.200 total wound area (cm^2) — p=0.35
Chronic Obstructive Pulmonary Disease
Primary: Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 22 to 24 Hours Post-dose on Day 2 — 1.49; 1.48; 1.45…
Persistent Asthma
Primary: Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) After Two Weeks of Treatment — 0.156; 0.197; 0.199; -0.005 Liters
Asthma
Primary: Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 22 to 24 Hours Post-dose on Day 2 — 2.31; 2.28; 2.24…
Urethritis
Primary: Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea — 3; 4; 0; 4 Participants
Asthma
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose for Each Treatment — 2.97; 2.93; 2.91; 2.77 Liters
Fatigue · End Stage Renal Disease (ESRD)
Primary: Reduction in Endotoxin Levels. — 5; 5 Participants
Herpes Zoster
Primary: Number of Participants With Serious Adverse Events (SAE) — 21; 11 Participants
Transfusional Iron Overload · β-thalassemia Major · Pediatric Rare Anemia
Primary: Participants With Adverse Events by Primary System Organ Class (SOC) — 20; 20; 19; 20 participants
Staphylococcus Aureus Infection
Primary: Geometric Mean Fold-rise (GMFR) in 0657n-specific Immunoglobulin G (IgG) Antibody Concentration From Baseline to 28 Days After the Administration of the Second V710…
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) — 21 participants